Atrial Fibrillation in 2024: The Latest
Evidence and Recommendations
Tuesday, 15 October 2024
Middle East, Russia and Africa
(MERA) Session
Professor Renato D. Lopes
Professor of Medicine
Department of Medicine of the Division of Cardiology, Duke University Medical Center,
North Carolina, United States of America
Country/region
Morocco, Nigeria
17:00–17:45
South Africa
18:00–18:45
Bahrain, Egypt, Iraq, Jordan,
Kuwait, Lebanon, Qatar,
Russia*, Saudi Arabia, Turkey
19:00–19:45
Oman, United Arab Emirates
20:00–20:45
*time zone based on Moscow, Standard Time (UTC +3)
Tuesday, 15 October 2024
Asia Session
Professor Renato D. Lopes
Professor of Medicine
Department of Medicine of the Division of Cardiology, Duke University Medical Center,
North Carolina, United States of America
Country/region
Pakistan
16:15–17:00
India
16:45–17:30
Indonesia*, Thailand, Vietnam
18:15–19:00
Hong Kong, Malaysia, Philippines,
Singapore, Taiwan
19:15–20:00
*time zone based on Western Indonesia (UTC +7)
Wednesday, 16 October 2024
Latin America (LATAM)
Session
Professor Renato D. Lopes
Professor of Medicine
Department of Medicine of the Division of Cardiology, Duke University Medical Center,
North Carolina, United States of America
Country/region
Costa Rica, Guatemala, Mexico*
18:00–18:45
Colombia, Ecuador**, Panama, Peru
19:00–19:45
Bolivia, Dominican Republic
20:00–20:45
Argentina, Brazil †, Chile ‡, Paraguay, Uruguay
21:00–21:45
*time zone based on Mexico City, Central Standard Time (UTC -6)
**time zone based on Quito, Ecuador Time (UTC -5)
†time zone based on São Paulo, Brasilia Time (UTC -3)
‡time zone based on Santiago, Chile Summer Time (UTC -3)
OBJECTIVES
Gain insights into the latest scientific evidence in
device-detected atrial fibrillation and their relevance
to cardiologists in clinical practice.
Discuss the findings of studies investigating the management of
patients with device-detected atrial fibrillation, including the
ARTESIA study, and their impact on clinical decision-making.
Review the 2024 ESC atrial fibrillation guidelines
related to device-detected atrial fibrillation and explore
their implications on treatment strategies and patient management.
AGENDA
Should Cardiologists Know?
Including the ARTESIA Study: How Does It
Contribute to Clinical Practice?
Atrial Fibrillation Guidelines for Device-detected Atrial Fibrillation